Sonova Holding AG stock faces revenue pressure after 2025 full-year results despite margin gains

Sonova Holding AG (ISIN: CH0012549785) reported full-year 2025 financials showing an 8% revenue decline to 360.2 million amid challenging market conditions, though EBITDA margin improved slightly. US investors should note the company's global hearing care leadership and potential rebound in 2026 guidance.

Sonova Holding AG, the Swiss hearing care leader, released its full-year 2025 financial results on March 23, 2026, revealing an 8% drop in sales revenue to 360.2 from 392.3 the prior year. Despite the revenue setback, the company posted a slight EBITDA margin expansion to 14.1%, up 0.2 percentage points, signaling operational resilience in a tough environment. For US investors, this matters now because Sonova's Phonak and Unitron brands hold significant US market share in the growing $10 billion hearing aid sector, where aging demographics and OTC regulations could drive future uptake.

As of: 24.03.2026

By Dr. Elena Voss, Senior Healthcare Equity Analyst: Sonova's margin discipline amid revenue headwinds underscores its competitive edge in audiology innovation.

Full-Year 2025 Breakdown: Revenue Miss but Profitability Holds

Sonova's consolidated sales fell 8% to 360.2 million in 2025, reflecting softer demand across hearing instruments and consumer hearing channels. Gross profit I climbed to a 49.5% margin from 46.5%, a 3.0 percentage point gain driven by cost controls and premium product mix shifts. EBITDA dipped 6% to 48.8 million, yet the margin edged up to 14.1%, highlighting efficiency gains.

Net profit slid to 16.2 million from 19.2 million, pressured by higher operating expenses. Balance sheet strength persisted with total assets at 327.8 million, down marginally from 331.6 million. Free cash flow improved, supporting dividend capacity for shareholders.

In Q4 2025, revenue rose to 97.7 million from 88.8 million, a solid 10% gain, with profit before tax surging 75% to 8.1 million. This quarter-end momentum suggests seasonal recovery in retail channels.

Divisional Performance Reveals Segment Shifts

Hearing Instruments division, Sonova's core, saw revenue pressures but maintained gross margins near 49%. Consumer Hearing posted stronger Q4 growth, benefiting from direct-to-consumer trends. Bruttogewinn II figures indicated improved profitability in select segments.

Overall, the company navigated inventory adjustments and economic slowdowns, with sales and marketing expenses contained. This divisional resilience positions Sonova for targeted growth in high-margin areas like premium hearing aids.

Management emphasized progress in operational efficiencies, which offset volume declines. For US investors, the US represents a key growth market, with Phonak's over-the-counter offerings aligning with FDA's 2022 rule changes expanding access.

2026 Outlook: Margin Expansion in Focus

The board anticipates EBITDA margin growth at group level in 2026, building on 2025 advances. This guidance reflects confidence in cost discipline, supply chain optimizations, and new product launches. Revenue recovery is implied through normalized demand post-inventory corrections.

Sonova plans to leverage AI-driven hearing solutions and tele-audiology, trends gaining traction in the US. Analysts will watch for confirmation in upcoming quarters, particularly US channel performance.

Capital allocation remains shareholder-friendly, with potential for increased payouts if cash flow sustains. This outlook tempers the revenue disappointment, focusing investor attention on profitability levers.

Why US Investors Should Watch Sonova Closely

Sonova commands about 20% global hearing aid market share, with strong US penetration via Phonak clinics and retail partnerships. The US hearing aid market, valued at over $5 billion, grows at 5-7% annually due to 30 million untreated cases among baby boomers.

Recent OTC deregulation allows sub-$2,000 self-fitting devices, where Sonova's tech stack excels. US sales, roughly 25% of group revenue, offer diversification from Europe amid CHF strength.

For ADR holders or ETF exposure, Sonova provides pure-play audiology without medtech dilution. Current valuation, post-results, may present entry for growth-oriented portfolios eyeing demographic tailwinds.

Competitive Landscape and Market Dynamics

Sonova competes with WS Audiology, Demant, and GN Store Nord in a consolidating sector. Its R&D spend, around 8-10% of sales, fuels innovations like rechargeable platforms and Bluetooth integration.

Post-pandemic, reimbursement expansions in Medicare Advantage boost adoption. Supply chain disruptions eased, but raw material costs linger as headwinds.

US investors benefit from Sonova's 40% non-European revenue mix, hedging Eurozone slowdowns. Strategic M&A, like recent clinic acquisitions, enhances distribution.

Risks and Open Questions Ahead

Persistent revenue softness risks guidance misses if consumer spending weakens. Currency volatility, with USD strength, impacts reported CHF figures. Regulatory shifts in OTC could favor low-cost entrants.

Debt levels, while manageable, warrant monitoring amid capex for growth. Competition intensifies with big tech eyeing wearables.

Key questions: Will Q1 2026 reverse revenue trend? Can margins reach 15%+? US execution remains pivotal.

Geopolitical tensions disrupt Asia supply chains, a 15% revenue source. Recession fears cap premium pricing power.

Despite risks, Sonova's 25+ year profitability track record reassures. Investors should track April earnings for clarity.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.